The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 4, 2007, Pages 336-344

  Benchaoui, H A ^a   Cox, S R ^b   Schneider, R P ^c   Boucher, J F ^b   Clemence, R G ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERENIA; CJ 18,518; DRUG METABOLITE; MAROPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; FEEDING; FEMALE; FIRST PASS EFFECT; KINETICS; LIVER CLEARANCE; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; URINALYSIS; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIEMETICS; AREA UNDER CURVE; DOGS; FEMALE; INJECTIONS, SUBCUTANEOUS; MALE; QUINUCLIDINES; RECEPTORS, NEUROKININ-1;

CANIS FAMILIARIS;

EID: 34347375088     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00877.x     Document Type: Article

References (17)

1. Benchaoui, H.A., Siedek, E.M., De la Puente-Redondo, V.A., Tilt, N., Rowan, T.G. Clemence, R.G. (2007) Confirmation of the efficacy of maropitant for the prevention of emesis associated with motion sickness in dogs presenting as clinical patients. The Veterinary Record, in press.
2. Bergman, A.J., Marbury, T., Fosbinder, T., Swan, S., Hickey, L., Bradstreet, T.E., Busillo, J., Petty, K.J., Aiyer, J.V., Constanzer, M., Huskey, S.W. Majumdar, A. (2005) Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clinical Pharmacokinetics, 44, 637 647.
3. Bergstrom, M., Hargreaves, R.J., Burns, H.D., Goldberg, M.R., Scibberas, D., Reines, S.A., Petty, K.J., Ogren, M., Antoni, G., Langstrom, B., Eskola, O., Scheinin, M., Solin, O., Majumdar, A.K., Constanzer, M.L., Battisti, W.P., Bradstreet, T.E., Gargano, C. Hietala, J. (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry, 55, 1007 1012.
4. De la Puente-Redondo, V., Clemence, R.G. Ramsey, D.S. (2006) Maropitant (CERENIATM) Provides Robust Preventative and Therapeutic Antiemetic Efficacy in Dogs from 30 Minutes to 24 Hours after a Single Dose. Proceedings of the European College of Veterinary Internal Medicine, ECVIM, Amsterdam, The Netherlands.
5. De la Puente-Redondo, V., Siedek, E.M., Benchaoui, H.A., Tilt, N., Rowan, T.G. Clemence, R.G. (2007a) The anti-emetic efficacy of maropitant (CereniaTM) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. Journal of Small Animal Practice, 48, 93 98.
6. De la Puente-Redondo, V., Tilt, N., Rowan, T.G. Clemence, R.G. (2007b) Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. American Journal of Veterinary Research, 68, 48 56.
7. Diemunsch, P. Grélot, L. (2000) Potential of substance P antagonists as antiemetics. Drugs, 60, 533 546.
8. Hellriegel, E.T., Bjornsson, T.D. Hauck, W.W. (1996) Interpatient variability in bioavailability is related to the extent of absorption: implication for bioavailability and bioequivalence studies. Clinical Pharmacology and Therapeutics, 60, 601 607.
9. Hietala, J., Nyman, M.J., Eskola, O., Laakso, A., Gronroos, T., Oikonen, V., Bergman, J., Haaparanta, M., Forsback, S., Marjamaki, P., Lehikoinen, P., Goldberg, M., Burns, D., Hamill, T., Eng, W.S., Coimbra, A., Hargreaves, R. Solin, O. (2005) Visualization and quantification of neurokinine-1 (NK1) receptors in the human brain. Molecular Imaging and Biology, 7, 262 272.
10. Majumdar, A.K., Howard, L., Goldberg, M.R., Hickey, L., Constanzer, M., Rothenberg, P.L., Crumley, T.M., Panebianco, D., Bradstreet, T.E., Bergman, A.J., Waldman, S.A., Greenberg, H.E., Butler, K., Knops, A., De Lepeleire, I., Michiels, N. Petty, K.J. (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of Clinical Pharmacology, 46, 291 300.
11. OECD (1998) Principles of Good Laboratory Practice (as revised in 1997). Environmental Directorate, Organisation for Economic Co-operation and Development, Paris. Series on Principles of Good Laboratory Practice and Compliance Monitoring No. 1. OECD Environmental Health and Safety Publications, ENV/MC/CHEM(98)17, Paris.
12. Patel, L. Lindley, C. (2003) Aprepitant-a novel NK1-receptor antagonist. Expert Opinion on Pharmacotherapy, 4, 2279 2296.
13. Reed-Hagen, A.E., Tsuchiya, M., Shimada, K., Wentland, J.-A. Obach, R.S. (1999) Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites. Biopharmaceutics and Drug Disposition, 20, 429 439.
14. Smith, B.J., Doran, A.C., McLean, S., Tingley, F.D., O'Neill, B.T. Kajiji, S.M. (2001) P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. Journal of Pharmacology and Experimental Therapeutics, 298, 1252 1259.
15. Toutain, P.L. Bousquet-Mélou, A. (2004a) Bioavailability and its assessment. Journal of Veterinary Pharmacology and Therapeutics, 27, 455 466.
16. Toutain, P.L. Bousquet-Mélou, A. (2004b) Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27, 415 425.
17. VICH (GCP) (2000) International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. Good Clinical Practice, Brussels, June 2000, effective 01 July 2001.